Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Plasma cell 1

Conditions

Multiple Myeloma 108Precursor Cell Lymphoblastic Leukemia-Lymphoma 24Leukemia 15Lymphoma 14Burkitt Lymphoma 14Recurrence 10Lymphoma, Non-Hodgkin 10Lymphoma, Mantle-Cell 10Waldenstrom Macroglobulinemia 9Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 8Immunoglobulin Light-chain Amyloidosis 8Neoplasms, Plasma Cell 6Lymphoma, Large B-Cell, Diffuse 6Lymphoma, B-Cell, Marginal Zone 6Smoldering Multiple Myeloma 5Neoplasms 5Lymphoma, Follicular 5Leukemia, Biphenotypic, Acute 5Hodgkin Disease 5Neoplasm Metastasis 4Nausea 4Breast Neoplasms 4Vomiting 3Renal Insufficiency 3Lymphoma, Large-Cell, Anaplastic 3Leukemia, Plasma Cell 3Leukemia, Lymphocytic, Chronic, B-Cell 3Hematologic Neoplasms 3Brain Neoplasms 3Blast Crisis 3

Interventions

XENP 1595 2Dexamethasone 2pomalidomide 1fasudil 1birtamimab 1Melphalan 1Calcium Dobesilate 1Bortezomib 17-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × Alzheimer Disease × Calcium Dobesilate × Clear all
NCT01083316 2020-09-25

Bortezomib and Dexamethasone Followed by High-Dose Melphalan and Stem Cell Transplantation for Primary (AL) Amyloidosis

Boston Medical Center

Phase 2 Completed
35 enrolled 9 charts
Plasma cell

Immunoglobulin Light-chain Amyloidosis, Alzheimer Disease, Amyloidosis

Data powered by HemOnc (CC BY 4.0) Colophon âš¡